Form 4: Regulus Therapeutics Director Disposes All Holdings Following Novartis Acquisition

A recent SEC Form 4 filing reveals Regulus Therapeutics Inc. Director Jason Raleigh Nunn has disposed of all his common stock and stock options in the company, effective June 25, 2025, as a direct result of the company's acquisition by Novartis AG.

Summary

• Jason Raleigh Nunn, a Director of Regulus Therapeutics Inc. (RGLS), reported the disposition of all his beneficial ownership in the company.
• The transactions occurred on June 25, 2025, coinciding with the completion of the merger between Regulus Therapeutics Inc. and Redwood Merger Sub Inc., a wholly-owned indirect subsidiary of Novartis AG.
• Under the Merger Agreement dated April 29, 2025, all issued and outstanding shares of Regulus Therapeutics common stock were acquired for $7.00 in cash per share (the 'Closing Amount') plus one contingent value right (CVR) per share.
• Each CVR entitles the holder to receive an additional $7.00 in cash upon the achievement of a specified milestone.
• Mr. Nunn disposed of 62,500 shares of common stock, which were converted into the Offer Price ($7.00 cash + one CVR per share).
• All outstanding and unexercised stock options were also canceled and converted based on their exercise price relative to the Closing Amount.
• In-the-Money Options (exercise price less than $7.00) were converted into a cash payment (Closing Amount minus exercise price) plus one CVR per share.
• Out-of-the-Money Options (exercise price equal to or greater than $7.00 but less than $14.00) were converted into one CVR per share, with a potential future cash payment if the CVR milestone is met.
• Specific stock options disposed include: 4,650 at $6.4, 2,325 at $8.8, 4,000 at $9.9, 9,000 at $2.7, 30,000 at $1.45, 15,000 at $1.36, 30,000 at $2.01, and 60,000 at $2.01.
• Following these transactions, Mr. Nunn holds 0 shares of common stock and 0 derivative securities in Regulus Therapeutics Inc.

Sentiment

Score: 7

Explanation: The sentiment is generally positive for shareholders as the company was acquired at a premium (implied by the offer price), providing liquidity and potential upside via the CVR. However, it's neutral from the perspective of Regulus's independent future, as it no longer exists as a standalone public entity.

Positives

• Shareholders of Regulus Therapeutics Inc. received a cash payment of $7.00 per share, providing immediate liquidity and a defined return.
• The inclusion of a Contingent Value Right (CVR) offers shareholders potential for an additional $7.00 per share, providing upside linked to future milestone achievement.
• The acquisition by Novartis AG provides a clear exit strategy and valuation for Regulus Therapeutics shareholders.

Negatives

• Regulus Therapeutics Inc. ceases to be an independent publicly traded company, eliminating future independent growth potential for its shareholders.
• The additional $7.00 per share from the CVR is contingent upon a specific milestone being met, meaning there is no guarantee of receiving the full potential offer price of $14.00 per share.
• Shareholders no longer participate in the future operational successes or failures of Regulus Therapeutics as an independent entity.

Risks

• The primary risk is that the milestone specified in the CVR Agreement may not be achieved, in which case the contingent payment of $7.00 per CVR will not be made.
• Out-of-the-Money Options will only yield a cash payment if the CVR milestone is met and the $14.00 threshold is exceeded relative to their exercise price.

Future Outlook

Regulus Therapeutics Inc. has become a wholly-owned subsidiary of Novartis AG, meaning its independent operational and strategic future outlook is now integrated within Novartis. The future financial outcome for former Regulus shareholders is tied to the achievement of the CVR milestone.

Industry Context

This acquisition highlights ongoing consolidation within the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies like Novartis acquire smaller biotech firms to expand their pipelines and intellectual property portfolios. Such mergers often provide an exit for early investors and a strategic asset for the acquirer.

Comparison to Industry Standards

• The deal structure, combining an upfront cash payment with a contingent value right (CVR), is a common mechanism in biotech acquisitions, particularly when the acquired company's value is tied to the success of specific clinical milestones or regulatory approvals. This allows the acquirer to mitigate risk while offering potential upside to the target's shareholders.
• Specific comparable companies or projects are not detailed in this Form 4 filing, as it focuses on insider transaction reporting rather than deal rationale or valuation benchmarks.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received cash and CVRs for their shares and options, providing a defined return on their investment.
• Employees (holding options/RSUs): Compensated for their equity holdings as per the merger agreement terms.
• Company (Regulus Therapeutics Inc.): Now operates as a wholly-owned subsidiary of Novartis AG, integrating its operations and strategic direction within the larger parent company.

Next Steps

• Monitoring the achievement of the milestone specified in the CVR Agreement, which would trigger the contingent cash payment of $7.00 per CVR.

Key Dates

Keywords

SEC Form 4, Merger, Acquisition, Regulus Therapeutics, Novartis AG, RGLS, Contingent Value Right, CVR, Insider Transaction, Beneficial Ownership, Stock Options, Common Stock